Syndax Pharmaceuticals (SNDX) Cash & Current Investments (2015 - 2026)

Syndax Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $352.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 122.67% year-over-year to $352.1 million; the TTM figure through Mar 2026 stood at $352.1 million (up 122.67% YoY), while the FY2025 annual figure was $394.1 million, up 140.12% from the prior year.
• Cash & Current Investments was $352.1 million for Q1 2026 at Syndax Pharmaceuticals, down from $394.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $570.7 million in Q4 2023 to a low of $74.5 million in Q4 2022.
• Historically, Cash & Current Investments has averaged $311.7 million across 5 years, with a median of $363.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments surged 666.34% in 2023, then slumped 71.77% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $74.5 million in 2022, then soared by 666.34% to $570.7 million in 2023, then slumped by 71.24% to $164.1 million in 2024, then surged by 140.12% to $394.1 million in 2025, then decreased by 10.66% to $352.1 million in 2026.
• The last three Cash & Current Investments figures came in at $352.1 million (Q1 2026), $394.1 million (Q4 2025), and $135.0 million (Q3 2025), per Business Quant data.